Clinical trials: Pancreatic Cancer Stage
Pancreatic Cancer Stage II
Abraxane and Gemcitabine Versus Gemcitabine Alone in Locally Advanced Unresectable Pancreatic Cancer.
Pancreatic cancer is the fourth cause of cancer mortality: there are different treatment approaches to locally advanced pancreatic cancer management.
- Trial name
- GAP (NCT02043730)
- Testing
- Nab-paclitaxel and Gemcitabine, Gemcitabine
- Where
- 39 sites in Italy
- Volunteers
- 124 people
- Sponsor
- Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente
Gastric Cancer, Pancreatic Cancer
Radiation Therapy and Chemotherapy in Treating Patients With Cancer of the Pancreas or Stomach
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00003157
- Testing
- cisplatin, gemcitabine hydrochloride, radiation therapy
- Where
- 18 sites in United States
- Volunteers
- 26 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Metastatic Cancer, Solid Tumor
Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies
The primary purpose of this study is to see if Sym024 is safe and tolerable as monotherapy and in combination with Sym021 in patients with solid tumor malignancies.
- Trial name
- NCT04672434
- Testing
- Sym021, Sym024
- Where
- 4 sites in United States, Canada
- Volunteers
- 48 people
- Sponsor
- Symphogen A/S
Unresectable Locally Advanced or Metastatic Pancreatic Cancer
Surufatinib Combined With KN046 and AG Regimen Chemotherapy as First-Line Treatment for Unresectable Advanced Pancreatic Cancer
Advanced pancreatic cancer is a highly aggressive and fatal disease with an extremely low 5-year survival rate. Combined chemotherapy is the mainstay of treatment for patients with unresectable advanced pancreatic cancer, and the…
- Trial name
- NCT05832892
- Testing
- surufatinib, KN046, gemcitabine
- Where
- China
- Volunteers
- 41 people
- Sponsor
- Shanghai Zhongshan Hospital
Prostate Cancer, Pancreatic Cancer
Phase I Study to evaluate124I-A11 PSCA Minibody in Patients With Metastatic Prostate, Bladder and Pancreatic Cancer
The purpose of the study is to determine whether positron emission tomography (PET), using the new imaging drug [124 I] PSCA-Minibody can be used for imaging prostate, pancreatic or bladder cancer that has spread to the bones and…
- Conditions
- Prostate Cancer, Pancreatic Cancer, Bladder Cancer
- Trial name
- NCT02092948
- Testing
- [124I] PSCA-Minibody PET/CT imaging of the whole body
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Pancreatic Cancer, Stage IV Pancreatic Cancer
A Study of Vantictumab (OMP-18R5) in Combination With Nab-Paclitaxel and Gemcitabine in Previously Untreated Stage IV Pancreatic Cancer
This is an open-label Phase 1b dose-escalation study to assess the safety, tolerability, and PK of vantictumab when combined with nab-paclitaxel and gemcitabine.
- Trial name
- NCT02005315
- Testing
- Vantictumab, Nab-Paclitaxel, Gemcitabine
- Where
- 5 sites in United States
- Volunteers
- 30 people
- Sponsor
- OncoMed Pharmaceuticals, Inc.
Locally Advanced Pancreatic Adenocarcinoma, Borderline Resectable Pancreatic Carcinoma
Standard or Prolonged Neoadjuvant Chemotherapy Before Surgery for BR/LAPC
The goal of this multicenter randomized controlled phase III trial is to compare two durations of neoadjuvant chemotherapy (NAT) with mFOLFIRINOX or gemcitabine-nab-paclitaxel (GnP) before attempt for surgical resection in…
- Conditions
- Locally Advanced Pancreatic Adenocarcinoma, Borderline Resectable Pancreatic Carcinoma, Pancreas Cancer, Neoadjuvant Chemotherapy
- Trial name
- ADVANTAGE (NCT06714604)
- Testing
- FOLFIRINOX or gemcitabine-nab-paclitaxel
- Where
- Sweden
- Volunteers
- 432 people
- Sponsor
- Sahlgrenska University Hospital
Pancreatic Adenocarcinoma, Liver Metastases
Hepatic Artery Infusional Floxuridine to Treat Pancreatic Cancer Liver Metastases
This is a single arm, phase II study without blinding. The purpose is to determine the impact of hepatic artery infusion Floxuridine (FUDR) on liver metastases from pancreatic adenocarcinoma.
- Trial name
- NCT03856658
- Testing
- Floxuridine (FUDR), Hepatic Artery Infusion Pump, Heparinized Saline
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Corewell Health West
Neuroendocrine Cancer
Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers
The purpose of this study is to determine if carfilzomib is safe and effective in the treatment of patients with advanced neuroendocrine tumors.
- Trial name
- NCT02318784
- Testing
- Carfilzomib
- Where
- 10 sites in United States
- Volunteers
- 62 people
- Sponsor
- SCRI Development Innovations, LLC
Pancreatic Cancer
A Phase II Study of Combine Modality Therapy in Locally Advanced Pancreatic Cancer
Induction chemotherapy will be administered every 2 weeks for 6 cycles (about 3 months). Patients who have radiological evidence of progressive disease will be shifted to salvage chemotherapy.
- Trial name
- NCT00149578
- Testing
- Gemcitabine Oxaliplatin 5FU and Leucovorin
- Where
- 2 sites in Taiwan
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- National Health Research Institutes, Taiwan
Stage III Pancreatic Cancer
A Registry Study of NanoKnife IRE for Stage 3 Pancreatic Cancer
This multicenter, observational study will evaluate the effectiveness and safety of the NanoKnife System when used for the ablation of Stage 3 pancreatic adenocarcinoma (Stage 3 PC).
- Trial name
- DIRECT (NCT03899649)
- Testing
- SOC, NanoKnife System
- Where
- 14 sites in United States
- Volunteers
- 532 people
- Sponsor
- Angiodynamics, Inc.
Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer
Phase I - Escalating Dose Study of siG12D LODER (Local Drug EluteR) in Patients With Locally Advanced Adenocarcinoma of the Pancreas, and a Single Dose Study of siG12D LODER (Local Drug EluteR) in Patients With Non-operable Adenocarcinoma of the Pancreas
Phase 0 - Open label, Single dose study of siG12D LODER in Patients with operable adenocarcinoma of the pancreas. The primary endpoint: To assess efficacy and local distribution of siRNA out of eight high dose siG12D LODERs in…
- Trial name
- NCT01188785
- Testing
- siG12D LODER
- Where
- 3 sites in Israel
- Volunteers
- 15 people
- Sponsor
- Silenseed Ltd
Pancreatic Cancer, Metastatic
OSI-906 With Gemcitabine and Erlotinib for Metastatic Ductal Adenocarcinoma of the Pancreas
OSI-906 is a new drug that may stop cancer cells from growing abnormally. This drug has been used in other research studies and information from those suggests that OSI-906 may help block cell receptors involved in tumor growth.
- Trial name
- NCT01600807
- Testing
- Gemcitabine, Erlotinib, OSI-906, Gemcitabine, Erlotinib
- Where
- 2 sites in United States
- Sponsor
- Dana-Farber Cancer Institute
Metastatic Pancreatic Adenocarcinoma
A Phase 1 Trial Of Safety And Initial Efficacy Of Vagal Nerve Blockade For Cancer-Induced Cachexia In Patients With Metastatic Pancreatic Adenocarcinoma
The goal of this clinical research study is to learn about the safety and tolerability of the OnVagus device when used by patients who have metastatic pancreatic cancer and are receiving chemotherapy.
- Trial name
- NCT07700212
- Testing
- Transcutaneous LFVB (tLFVB)
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- M.D. Anderson Cancer Center
Stage IA Pancreatic Cancer, Stage IB Pancreatic Cancer
Neoadjuvant SBRT With Concomitant Capecitabine in Resectable Pancreatic Cancer
This phase I trial studies the side effects and best dose of stereotactic body radiation therapy when given together with capecitabine before surgery in treating patients with pancreatic cancer that can be removed by surgery.
- Conditions
- Stage IA Pancreatic Cancer, Stage IB Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer
- Trial name
- NCT01918644
- Testing
- stereotactic body radiation therapy, capecitabine, therapeutic conventional surgery
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- University of Wisconsin, Madison
Gastrointestinal Carcinoid Tumor, Islet Cell Tumor
PS-341 in Treating Patients With Metastatic Neuroendocrine Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of PS-341 in treating patients who have metastatic…
- Trial name
- NCT00017199
- Testing
- bortezomib
- Where
- 2 sites in United States
- Sponsor
- Ohio State University Comprehensive Cancer Center
Gastrinoma, Glucagonoma
Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With Surgery
This randomized phase II trial studies how well everolimus works in treating patients with pancreatic neuroendocrine tumors metastatic to the liver previously treated with surgery.
- Conditions
- Gastrinoma, Glucagonoma, Insulinoma, Liver Metastases
- Trial name
- NCT02031536
- Testing
- everolimus
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Pancreatic Cancer
Cetuximab, Gemcitabine, and Oxaliplatin Followed By Surgery or External-Beam Radiation Therapy and Capecitabine in Treating Patients With Locally Advanced, Nonmetastatic Pancreatic Cancer That Cannot Be Removed By Surgery
RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00408564
- Testing
- cetuximab, capecitabine, oxaliplatin
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Medical University of South Carolina
Pancreatic Neoplasms, Hepatic Metastasis of Pancreatic Cancer
Hepatic Arterial Infusion of Sodium Bicarbonate (NaHCO3) Combined With NASOX Regimen and Programmed Death-1 (PD-1) Inhibitors for Pancreatic Cancer Liver Metastases
This Phase II clinical study evaluates the safety and efficacy of a combination therapy for patients with pancreatic cancer that has spread to the liver.
- Trial name
- NCT07504471
- Testing
- pH-NASOX-Immune Group
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Ruijin Hospital
Pancreatic Cancer
Postoperative Proton Radiotherapy With Chemo for Pancreatic Cancer
The purpose of this study is to find out what effects, good and/or bad, proton radiation combined with chemotherapy has on resected pancreatic cancer.
- Trial name
- PC03 (NCT01553019)
- Testing
- Proton radiation, Gemcitabine
- Where
- 2 sites in United States
- Volunteers
- 2 people
- Sponsor
- University of Florida
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.